Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1991 May;29(5):1038–1041. doi: 10.1128/jcm.29.5.1038-1041.1991

Aspergillus fumigatus contamination of lymphokine-activated killer cells infused into cancer patients.

P M Arnow 1, S G Houchins 1, J M Richards 1, R Chudy 1
PMCID: PMC269930  PMID: 2056038

Abstract

Lymphokine-activated killer (LAK) cells, prepared by incubating autologous lymphocytes in cell culture medium with interleukin-2, selectively lyse tumor cells and are effective immunotherapy of some cancers. During a 3-month period, two patients at our center were infused with LAK cells subsequently found to have been contaminated by Aspergillus fumigatus. Each case was investigated by obtaining environmental cultures and assessing aseptic practices during LAK cell preparation. Investigation of the first case demonstrated a malfunction of the laminar air flow hood, under which interleukin-2 and the patient's lymphocytes had been added to cell culture medium, and showed heavy A. fumigatus contamination of the hood, adjacent countertop, and cell culture incubator. Despite repair of the laminar air flow hood and cleaning of the laboratory, a second case occurred, and cultures at that time implicated the humidified cell culture incubators as the source of A. fumigatus. Following incubator sterilization and removal of the humidification apparatus from the incubators, weekly environmental cultures in the LAK cell laboratory were negative, and none of the LAK cell cultures from the 20 patients treated during the ensuing 15 months grew A. fumigatus. Our findings show that growth of fungi in humidified incubators, which previously has caused contamination problems in tissue culture and clinical microbiology laboratories, can result in patient infections when humidified incubators are used to prepare cells for reinfusion.

Full text

PDF
1038

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clarke J. H., Norman J. A., Lavery E. Some observations on contamination of animal cell cultures by the fungus Aspergillus fumigatus and suggested control measures. Cell Biol Int Rep. 1989 Sep;13(9):773–779. doi: 10.1016/0309-1651(89)90054-4. [DOI] [PubMed] [Google Scholar]
  2. Daisy J. A., Abrutyn E. A., MacGregor R. R. Inadvertent administration of intravenous fluids contaminated with fungus. Ann Intern Med. 1979 Oct;91(4):563–565. doi: 10.7326/0003-4819-91-4-563. [DOI] [PubMed] [Google Scholar]
  3. Eberlein T. J., Schoof D. D., Jung S. E., Davidson D., Gramolini B., McGrath K., Massaro A., Wilson R. E. A new regimen of interleukin 2 and lymphokine-activated killer cells. Efficacy without significant toxicity. Arch Intern Med. 1988 Dec;148(12):2571–2576. [PubMed] [Google Scholar]
  4. Fisher R. I., Coltman C. A., Jr, Doroshow J. H., Rayner A. A., Hawkins M. J., Mier J. W., Wiernik P., McMannis J. D., Weiss G. R., Margolin K. A. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med. 1988 Apr;108(4):518–523. doi: 10.7326/0003-4819-108-4-518. [DOI] [PubMed] [Google Scholar]
  5. Klempner M. S., Noring R., Mier J. W., Atkins M. B. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med. 1990 Apr 5;322(14):959–965. doi: 10.1056/NEJM199004053221404. [DOI] [PubMed] [Google Scholar]
  6. Patterson T. F., Miniter P., Ryan J. L., Andriole V. T. Effect of immunosuppression and amphotericin B on Aspergillus antigenemia in an experimental model. J Infect Dis. 1988 Aug;158(2):415–422. doi: 10.1093/infdis/158.2.415. [DOI] [PubMed] [Google Scholar]
  7. Phillips P., Radigan G. Antigenemia in a rabbit model of invasive aspergillosis. J Infect Dis. 1989 Jun;159(6):1147–1150. doi: 10.1093/infdis/159.6.1147. [DOI] [PubMed] [Google Scholar]
  8. Robertson M. H. Fungi in fluids--a hazard of intravenous therapy. J Med Microbiol. 1970 Feb;3(1):99–102. doi: 10.1099/00222615-3-1-99. [DOI] [PubMed] [Google Scholar]
  9. Rosenberg S. A., Lotze M. T., Mulé J. J. NIH conference. New approaches to the immunotherapy of cancer using interleukin-2. Ann Intern Med. 1988 Jun;108(6):853–864. doi: 10.7326/0003-4819-108-6-853. [DOI] [PubMed] [Google Scholar]
  10. Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  11. Todd N. J., Millar M. R., Dealler S. R., Wilkins S. Inadvertent intravenous infusion of Mucor during parenteral feeding of a neonate. J Hosp Infect. 1990 Apr;15(3):295–297. doi: 10.1016/0195-6701(90)90039-q. [DOI] [PubMed] [Google Scholar]
  12. Weisfuse I. B., Graham D. J., Will M., Parkinson D., Snydman D. R., Atkins M., Karron R. A., Feinstone S., Rayner A. A., Fisher R. I. An outbreak of hepatitis A among cancer patients treated with interleukin-2 and lymphokine-activated killer cells. J Infect Dis. 1990 Apr;161(4):647–652. doi: 10.1093/infdis/161.4.647. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES